The influence of P2Y₁₂ gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-07-02 DOI:10.1080/14796678.2024.2363712

Kornel Pawlak, Dorota Danielak, Paweł Burchardt, Łukasz Kruszyna, Marta Karaźniewicz-Łada

{"title":"The influence of P2Y12 gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention.","authors":"Kornel Pawlak, Dorota Danielak, Paweł Burchardt, Łukasz Kruszyna, Marta Karaźniewicz-Łada","doi":"10.1080/14796678.2024.2363712","DOIUrl":null,"url":null,"abstract":"Aim: We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention.Materials & methods: We used PCR-RFLP and PCR-ASO for P2Y12 genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units.Results: Studied polymorphisms had no statistically significant influence on PRU before (PRU0) and 6 months (PRU6) after the procedure. H1/H1 diabetic carriers had significantly higher PRU6 values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU6 values than H1/H2 non-obese carriers.Conclusion: We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"377-387"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457605/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2363712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention.Materials & methods: We used PCR-RFLP and PCR-ASO for P2Y₁₂ genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units.Results: Studied polymorphisms had no statistically significant influence on PRU before (PRU⁰) and 6 months (PRU⁶) after the procedure. H1/H1 diabetic carriers had significantly higher PRU⁶ values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU⁶ values than H1/H2 non-obese carriers.Conclusion: We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.

查看原文本刊更多论文

P2Y12基因多态性对经皮冠状动脉介入治疗后患者氯吡格雷治疗的影响。

目的：我们旨在明确经皮冠状动脉介入治疗患者的 P2Y12 多态性（rs6801273、rs2046934 和 rs6809699）、糖尿病、高血压、肥胖、高胆固醇血症、他汀类药物摄入量和吸烟习惯对氯吡格雷治疗的影响。材料与方法：我们使用 PCR-RFLP 和 PCR-ASO 进行 P2Y12 基因型分析。治疗效果采用 VerifyNow 方法进行测量，并以血小板反应性单位进行定义。研究结果所研究的多态性对手术前（PRU0）和手术后 6 个月（PRU6）的 PRU 没有统计学意义上的显著影响。H1/H1 糖尿病携带者的 PRU6 值明显高于非糖尿病患者。肥胖的 H1/H2 受试者的 PRU6 值明显低于非肥胖的 H1/H2 携带者。结论我们发现肥胖和糖尿病可能会影响抗血小板治疗的长期效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.